Pre-Market Safety Must Balance Statistics With Clinical Discernment – FDA
The next chapter for drug safety will be to more accurately quantify harm and risk in the pre-market setting, FDA's Office of Biostatistics Director Robert O'Neill said at a recent drug safety conference
You may also be interested in...
Outcomes trials appear to hold a strong position in the future of new drug development. But outcomes data is not the only factor FDA will consider as it moves toward setting new standards for quantification of risk and benefit, the agency said at a recent drug safety conference
Both FDA and industry are organizing databases to make the toxicities of known compounds available to the researchers making decisions in early development. Those efforts at computational toxicology are being met with a great deal of excitement
The International Fragrance Association North America took a break from its higher-stakes advocacy work Nov. 1 to give lawmakers and congressional staffers a "scent experience." Perfumers from six of the group's biggest members were on hand with "Scents of Home," joined by Monell Center researchers to educate attendees on the mechanics of scent and the important role it plays in people's lives.